Curasight

Curasight's CEO Ulrich Krasilnikoff comments:

"Throughout the first three quarters of 2024, we have built upon last year's successes, fortifying Curasight's role in radiopharmaceuticals. Key milestones include enrolling our first patient in the Phase II trial of uTRACE for prostate cancer and furthering our partnership with Curium, where we received a second milestone payment under the collaboration. Additionally, we announced a capital raise designed to enhance our financial position, and extending our cash runway well into the latter half of 2025."

Q3 (2024-07-01 - 2024-09-30)

• Gross loss amounted to kDKK -6,135 (kDKK -6,551)
• Operating loss amounted to kDKK -8,099 (kDKK -8,465)
• Loss before tax amounted to kDKK -8,523 (kDKK -8,484)
• Loss for the period amounted to kDKK -7,148 (kDKK -6,618)
• Total assets amounted to kDKK 25,778 (kDKK 41,913)
• Equity ratio amounted to 51.6% (90.1%)
• Earnings per share amounted to DKK -0.35 (DKK -0.33)

Q1-Q3 (2024-01-01 - 2024-09-30)

• Gross loss amounted to kDKK -22,521 (kDKK -20,236)
• Operating loss amounted to kDKK -28,443 (kDKK -25,307)
• Loss before tax amounted to kDKK -30,002 (kDKK -25,328)
• Loss for the period amounted to kDKK -25,877 (kDKK -19,756)
• Total assets amounted to kDKK 25,778 (kDKK 41,913)
• Equity ratio amounted to 51.6% (90.1%)
• Earnings per share amounted to DKK -1.25 (DKK -0.99)

Numbers in parenthesis are the numbers from the same period in 2023.